Person: ALSAN ÇETİN, İLKNUR
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ALSAN ÇETİN
First Name
İLKNUR
Name
36 results
Search Results
Now showing 1 - 10 of 36
Publication Open Access Oncological outcomes for encapsulated papillary carcinoma of the breast: Multicentric study of Turkish Society for Radiation Oncology breast cancer study group (TROD 06-014 study).(2022-12-04) ALSAN ÇETİN, İLKNUR; Gurdal N., Yildirim B. A. , Gursel O. K. , Ozkurt S., Ibis K., Gultekin M., Tepetam H., Gul S. K. , Guzeloz Z., Oksuz D. C. , et al.Publication Metadata only Kanser ile barışmak(Dünya Yayınları, 2023-02-01) ALSAN ÇETİN, İLKNUR; Alsan Çetin İ.Publication Open Access Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment(2022-08-01) AKIN TELLİ, TUĞBA; ÖZGÜVEN, SALİH; FİLİZOĞLU, NUH; ÖZTÜRK, MEHMET SAADEDDİN; ARIKAN, RUKİYE; DEMİRCAN, NAZIM CAN; BAŞOĞLU TÜYLÜ, TUĞBA; ALSAN ÇETİN, İLKNUR; ÖNEŞ, TUNÇ; DANE, FAYSAL; YUMUK, PERRAN FULDEN; AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T., et al.Objective We aimed to evaluate whether baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters could be used as predictive biomarkers for survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line treatment. Materials and methods This retrospective study included 54 mCRPC patients, who underwent baseline Ga-68-PSMA PET/CT imaging within 1 month before starting first-line treatment. Pre-treatment prostate-specific antigen (PSA) levels and treatments were recorded. SUVmax, SUVmean, whole-body PSMA-derived tumor volume (wbPSMA-TV), and whole-body total lesion PSMA (wbTL-PSMA) were calculated for all patients. PSA response was defined as a decline of >= 50% from pre-treatment value at 12 weeks. Overall survival (OS) was measured from the start of the first-line treatment for mCRPC. Results Docetaxel and abiraterone/enzalutamide were administered to 32 and 22 patients in the first-line setting, respectively. wbPSMA-TV (rho = 0.582, p = 0.004) and wbTL-PSMA (rho = 0.564, p = 0.007) showed moderate positive correlations with PSA levels. Older age (p = 0.02), higher wbPSMA-TV (p = 0.007), higher PSA (p = 0.01), higher number of bone metastases (p = 0.02), and lack of PSA response (p = 0.03) were significantly associated with an increased risk of mortality. Multivariate analysis determined wbPSMA-TV (HR: 1.003, 95% CI 1.001-1.004, p = 0.001) and PSA response (HR: 2.241, 95% CI 1.189-4.222, p = 0.01) as independent predictors of OS. Conclusion The wbPSMA-TV may be a useful tool to reflect tumor burden and predict survival outcomes in patients with mCRPC.Publication Metadata only SARS COV-2 pandemisi sırasında tedavi gören kanser hastaları ve yakınlarınınmemnuniyet, yaşam kaliteleri ve anksiyete durumlarının değerlendirilmesi: Kesitsel anket çalışması(2022-05-27) ALSAN ÇETİN, İLKNUR; şükürov t., akarcay M. K., Onaylar Z., anlar E., demir M., devran b. z., ALSAN ÇETİN İ.Publication Open Access Dosimetric comparison of anterior posterior-posterior anterior 2-field three-dimensional conformal radiotherapy, 4-field three-dimensional conformal radiotherapy and forward plan intensity modulated radiotherapy techniques in female lymphoma patients irradiated to neck and mediastinum(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2018) ALSAN ÇETİN, İLKNUR; Cini, Nilsu; Umay, Cenk; Ozdemir, Okan; Cetin, Ilknur Alsan; Epik, Hakan; Demiral, Ayse NurAim: Dosimetric comparison of three different techniques in female lymphoma patients who had radiotherapy (RT) to the neck and mediastinum. Setting and Design:: Retrospective clinical study. Materials and Methods: Computerized tomography-simulator images of eight patients were obtained retrospectively. Using 6 MV-X photon energy, RT plans were formed with three different techniques (anterior posterior-posterior anterior 2-field three-dimensional conformal RT [AP-PA 2-field 3D-CRT], 4-field 3D-CRT and forward plan intensity modulated RT [FPIMRT]). Comparisons were in terms of homogeneity index (HI), conformity index (CI), and inhomogeneity coefficient for planning target volume (PTV); mean lung dose, V-5Gy, V-10Gy, V-20Gy, V-30Gy for lung; D-mean, V-7.5Gy, V-15Gy, V-25Gy for heart; D-mean, V-3.5Gy, V-10Gy, V-20Gy for breast; D-max for spine; D-mean, V-10Gy, V-18Gy, V-25Gy, V-30Gy for thyroid. Statistical Analysis Used: Since nonparametric tests had to be used due to the study population being < 30, Friedman and Wilcoxon signed-rank tests were implemented in trilateral and bilateral comparison of techniques, respectively. For statistical significance, P value was required to be <0.05. Results: When FPIMRT was compared with AP-PA and 4-field techniques with respect to, HI (AP-PA/FPIMRT P: 0.017; 4-field/FPIMRT P: 0.03) and CI (AP-PA/FPIMRT P: 0.018; 4-field/FPIMRT P: 0.042), FPIMRT was more advantageous. In addition, FPIMRT was found more useful in terms of D-max (AP-PA/FPIMRT P: 0.012; 4-Field/FPIMRT P: 0.012) for spinal cord and D-mean (AP-PA/FPIMRT P: 0.012; 4-field/FPIMRT P: 0.012) for thyroid. Conclusion: FPIMRT was superior in terms of PTV homogeneity and conformity. However, it was observed that for normal tissues, FPIMRT was advantageous only for spinal cord and thyroid; but it was not the most advantageous technique for some of the dose-volume parameters of the breast, lung, and heart.Publication Metadata only Retrospective analysis of linac-based radiosurgery for arteriovenous malformations and testing of the Flickinger formula in predicting radiation injury(SPRINGER HEIDELBERG, 2012) ALSAN ÇETİN, İLKNUR; Cetin, I. A.; Ates, R.; Dhaens, J.; Storme, G.The aim of the study was to validate the use of linac-based radiosurgery in arteriovenous malformation (AVM) patients and to predict complications using an integrated logistic formula (ILF) in comparison with clinical outcomes. The results of radiosurgery in 92 AVM patients were examined. All patients were treated with linac-based radiosurgery. Of these, 70 patients were followed for 12-45 months (median, 24 months) and were analyzed. The treated volume varied from 0.09 to 26.95 cm(A3) (median, 2.3 cm(A3)) and the median marginal dose was 20 Gy (range, 10.4-22). The median 12-Gy volume was 9.94 cm(A3) (range, 0.74-60.09 cm(A3)). Patients and lesion characteristics potentially affecting nidus obliteration and excellent outcome were evaluated by performing a log-rank test and univariate and multivariate analyses. The risk for radiation injury (RRI) was calculated with an integrated logistic formula. The predictive power of the RRI was assessed by calculating the area under the receiver operating characteristic (ROC) curve. Follow-up magnetic resonance (MR) angiography revealed complete AVM obliteration in 56 of 70 patients. The MR angiography confirmed an obliteration rate of 80%. The annual hemorrhage rate was 1.4% for the first 2 years after radiosurgery and 0% thereafter. The number of patients with an excellent outcome was 48 (68%). Factors associated with better obliteration were higher radiation dose to the lesion margins [12-Gy volume (V12) > 10 cm(A3)], small volume, and a Pollock-Flickinger score less than 1.49; those predicting excellent outcomes were V12 < 10 cm(A3), small volume, and Pollock-Flickinger score less than 1.49, as determined by multivariate analyses. Factors associated with radiation injury were V12 > 10 cm(A3) (p=0.03) and volume greater than 2 cm(A3) (p=0.001), as determined by a univariate analysis. The analyses showed an ROC of 0.66. These data suggest that linac-based radiosurgery is effective. In terms of obliteration, excellent outcomes, and especially radiation injury, V12 and volume should be considered. The Flickinger formula seems to be applicable to Novalis-treated patients, but long-term follow-up is necessary for definite conclusions.Publication Metadata only Enkapsüler papiller meme karsinomunda onkolojik sonuçlar: (TROD 06-014 çalışması(2023-12-07) ALSAN ÇETİN, İLKNUR; GÜRDAL N., YILDIRIM B., kandemir gürsel o., özkurt s., İBİŞ K., GÜLTEKİN M., TEPETAM H., KARABULUT GÜL Ş., GÜZELÖZ ÇAPAR Z., ÇOLPAN ÖKSÜZ D., et al.Publication Metadata only Vulva tutulumu olan alveoler rabdomyosarkomu olgu sunumu(2023-12-07) ALSAN ÇETİN, İLKNUR; kornienko a., çeşmecioğlu e., ALSAN ÇETİN İ.Publication Open Access Breast Brachytherapy and a Case Report(KARE PUBL, 2019) ALSAN ÇETİN, İLKNUR; Cetin, Ilknur Alsan; Kucucuk, Seden; Aslay, IsikFor women who had breast-conserving surgery (BCS), brachytherapy can be used along with external beam radiation as a way to add an extra boost of radiation to the tumor site. It may also be used as a form of accelerated partial breast irradiation. Tumor size, location and other factors may affect brachytherapy decision. The patient was 47 years old and applied to Istanbul University Oncology Institute Radiation Oncology Department. A mass in the upper outer quadrant was detected. Invasive ductal cancer was diagnosed with biopsy. MKC and sentinel lymph node biopsy were performed in 2013. Histological and nuclear grade II, ER (+++), PG (+++), cerbB2 (-), lympho vascular invasion (-), pT1N0 was revealed. In 2013, 50 Gy/25 frx ERT was applied to the left breast tangent. After 16 days, HDR was performed twice daily (BID) (4x3Gy), 14-channel ISI breast implants. The reference dose is defined as 3 Gy GTV.Publication Open Access Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients(2022-11-01) ALSAN ÇETİN, İLKNUR; Alsan Çetin İ., Akay S. U. , Şengöz K. M.Background In this study, we investigated the ability of prostate-specific antigen (PSA) 12 months after (nPSA12) external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) to predict biochemical recurrence-free survival (BRFS), overall survival (OS), and prostate cancer-specific mortality (PCSM) in intermediateand high-risk prostate cancer patients. Methods We retrospectively reviewed the clinical data of 338 intermediate- and high-risk prostate cancer patients treated with EBRT with ADT at our institution between 2000 and 2018. The median radiation dose was 76 Gy, the median initial PSA level was 17 ng/mL (range, 1–228 ng/mL), and the median duration of ADT was 24 months (range, 6–167 months). The median PSA level 1 months after EBRT was 0.06 ng/mL (range, 0–25.6 ng/mL). Univariate and multivariate analyses were performed. Patient survival was assessed using the Kaplan-Meier method and Cox proportional hazards regression analyses. Results The median follow-up time was 5 years (range, 1–20 years). Multivariate analysis revealed that nPSA was an independent and significant factor associated with OS, PCSM, and BRFS (P = 0.008, P = 0.001, P = 0.04). Furthermore, the time to nPSA12 was an independent predictor of PCSM and BRFS (P = 0.042, P = 0.021). Pelvic irradiation was also significantly associated with worse OS and PCSM (P = 0.004, P = 0.01). Additionally, age (≤ 70 or > 70 years) and hormone therapy duration (6 months, 1–3 years, or > 3 years) were significantly associated with OS and PCSM, respectively (P = 0.004, P = 0.02). For high risk, nPSA and nPSA12 were an independent predictor for BRFS. (P = 0.021, P = 0.029) Conclusion The nPSA12 level of > 0.06 ng/mL may independently predict worse PCSM and BRFS in intermediateand high-risk prostate cancer patients undergoing EBRT and ADT. Additionally, for high risk, nPSA > 0.06 ng/mL and nPSA12 > 0.06 ng/mL may independently predict worse BRFS.